Absci Corporation (ABSI) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGS. Market cap 1.53B USD. 52-week range 2.24 to 12.05 USD. Data as of 2026-10-09.
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has ...